Movement Alert|Caris Life Sciences, Inc. Intraday Decline 5.2%, Post-Earnings Pressure Persists Despite Q3 Beat

Market Focus11-10

On November 10, Caris Life Sciences, Inc. fell 5.2% in Regular Trading, trading at $24.27 per share, with turnover of $18.96 million.

The move followed continued post-earnings pressure after the company reported third-quarter results above expectations but still showed a year-over-year EPS decline, while analyst views remained mixed.

Caris Life Sciences, Inc. reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million market forecast. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, EPS declined from $0.08 a year earlier, and recent analyst actions showed divergence, with Citigroup maintaining Buy and Piper Sandler maintaining Neutral.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment